{"id":"NCT02389816","sponsor":"Takeda","briefTitle":"A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Once Daily Oral Lu AA21004 in Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-04-10","primaryCompletion":"2018-03-16","completion":"2018-03-16","firstPosted":"2015-03-17","resultsPosted":"2019-06-26","lastUpdate":"2021-03-24"},"enrollment":493,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Vortioxetine","otherNames":["Lu AA21004"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vortioxetine 10 mg","type":"EXPERIMENTAL"},{"label":"Vortioxetine 20 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy of two fixed doses of vortioxetine (Lu AA21004; 10 or 20 mg/day) after 8 weeks of treatment in patients with major depressive disorder (MDD) in Japan.","primaryOutcome":{"measure":"Change From Baseline in Montgomery-Ã…sberg Depression Rating Scale (MADRS) Total Score to Week 8","timeFrame":"Baseline (At the start of double-blind treatment period), up to 8 weeks","effectByArm":[{"arm":"Placebo","deltaMin":-12.37,"sd":0.714},{"arm":"Vortioxetine 10 mg","deltaMin":-15.03,"sd":0.699},{"arm":"Vortioxetine 20 mg","deltaMin":-15.45,"sd":0.705}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0080"},{"comp":"OG000 vs OG002","p":"0.0023"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":47,"countries":["Japan"]},"refs":{"pmids":["35221687","34992372","34955641"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":161},"commonTop":["Nasopharyngitis","Nausea","Somnolence","Vomiting"]}}